Keiji Tanimoto

Last Updated :2018/11/01

Affiliations, Positions
Research Institute for Radiation Biology and Medicine, ., Assistant Professor
E-mail
ktanimohiroshima-u.ac.jp

Basic Information

Academic Degrees

  • Doctor of Philosophy in Dental Science, Hiroshima University

Research Fields

  • Medicine,dentistry, and pharmacy;Basic medicine;General medical chemistry
  • Medicine,dentistry, and pharmacy;Dentistry;Surgical dentistry

Research Keywords

  • transcription
  • HIF-1
  • HIF-1
  • Transcription
  • hypoxia
  • individualized therapy

Educational Activity

Course in Charge

  1. 2018, Undergraduate Education, Intensive, Practice for medical research
  2. 2018, Undergraduate Education, First Semester, Molecular Biology in Medicine
  3. 2018, Graduate Education (Master's Program) , First Semester, Molecular Biology and Radiological Science

Research Activities

Academic Papers

  1. Genetics of the hypoxia-inducible factors in human cancers., Experimental Cell Research, 356(2), 166-172
  2. The Krüppel-like zinc finger transcription factor, GLI-similar 1, is regulated by hypoxia-inducible factors via non-canonical mechanisms., Biochemical and Biophysical Research Communications, 441(2), 499-506
  3. An association study between Hypoxia inducible Factor-1alpha (HIF-1) polymorphisms and osteonecrosis, PLOS ONE, 8(11), e79647
  4. Electrical stimulation accelerates neuromuscular junction formation through ADAM19/neuregulin/ErbB signaling in vitro, Neuroscience Letters, 545, 29-34
  5. Development of lymphoproliferative diseases by hypoxia-inducible factor-1a is associated with prolonged lymphocyte survival, PLOS ONE, 8(4), e57833
  6. Abnormal FHIT Transcripts in Human Breast Carcinomas: A Clinicopathological and Epidemiological Analysis of 61 Japanese Case., Cancer Research, 57, 1981-1985, 19970401
  7. Antitumor Effect of Carboplatin Conbined with Radiation on Tumors in Mice., Anticancer Research, 17, 2535-2538, 19970401
  8. Regulation of estragen receptar alpha gene mediated by prometer B responsible for its enhanced expression in human breast cancer, Nucleic Acids Research, 27(3), 903-909, 19990401
  9. Polymorphisms of the CYP1A1 and GSTM1 gene involved in oral squamous cell carcinoma in association with a cigarette dose., European Journal of Cancer= Oral Oncology, 35, 191-196, 19990401
  10. Abnormal FHIT transcripts found in both lung cancer and normal lung tissue., Genes= Chromosomes and Cancer, 24, 105-111, 19990401
  11. Cellular sensitivity determinants to docetaxel in human gastrointestinal cancers, International Journal of Oncology, 20(2), 333-338, 20010201
  12. Unique action determinants of double acting topoisomerase inhibitor, TAS-103, International Journal of Oncology, 19(5), 921-927, 20011101
  13. O6-methylguanine-DNA methyltransferase (MGMT) as a determinant of resistance to camptothecin derivatives, Japanese Journal of Cancer Research, 93(1), 93-102, 20020101
  14. Identification of Functional Hypoxia Response Elements in Promoter Region of the DEC1 and DEC2 Gene, Journal of Biological Chemistry, 277(49), 47014-47021, 20021201
  15. Bcl-2 in cancer and normal tissue cells as a prediction marker of response to 5-fluorouracil, International Journal of Oncology, 22(1), 181-186, 20030101
  16. Identification of Residues Critical for Regulation of Protein Stability and the Transactivation Function of the Hypoxia-Inducible Factor-1a by the von Hippel-Lindau Tumor Suppresor Gene Product, Journal of Biological Chemistry, 278, 6816-6823, 20030401
  17. Targeted gene delivery to human osteosarcoma cells with magnetic liposomes under a magnetic field, INTERNATIONAL JOURNAL OF ONCOLOGY, 22, 1065-1071, 20030401
  18. The expression and function of estrogen receptor a and b in human breast cancer and its clinical application., Endocrine- Related Cancer, 10, 193-202, 20030401
  19. Hypoxia-Inducible Factor-1a Polymorphisms Associated with Enhanced Transactivation Capacity, Implying Clinical Significance., Carcinogenesis, 24, 20030401
  20. High-flow arteriovenous malformation of the mandible: treatment and 7-year follow-up, British Journal of Oral and Maxillofacial Surgery, 41, 348-350, 20030401
  21. Personalized Medicine, and Our Recent Approaches, Annals of Cancer Research and Therapy, 11, 61-72, 20031001
  22. Mutation of the von Hippel-Lindau (VHL) gene in human colorectal carcinoma: Association with cytoplasmic accumulation of hypoxia-inducible factor (HIF)-1a, Cancer Science, 95, 149-153, 20040401
  23. Aberrant Methylation of Dihydropyrimidine Dehydrogenase Gene (DPYD) Promoter, DPYD Expression, and Cellular Sensitivity to 5-fluorouracil in Cancer Cells, Clinical Cancer Research, 10, 7100-7107, 20040401
  24. Repression of PML Nuclear Body-Associated Transcription by Oxidative Stress-Activated Bach2, Molecular and Cellular Biology, 24(8), 3473-3484, 20040401
  25. Concise prediction models of anticancer efficacy of 8 drugs using expression data from 12 selected genes, International Journal of Cancer, 111(4), 617-626, 20040901
  26. Single nucleotide polymorphism in the hypoxia-inducible factor-1alpha gene in colorectal carcinoma, Oncology Reports, 1033-1037, 20041101
  27. Differential gene expressions during immortalization of normal human fibroblasts and endothelial cells transfected with human telomerase reverse transcriptase gene., Int J Oncol, 24, 1435-1442, 20041201
  28. Activator Protein Accelerates Dihydropyrimidine Dehydrogenase Gene Transcription in Cancer Cells, Cancer Research, 65, 1055-1062, 20050401
  29. Differentially expressed genes throughout the cellular immortalization processes are quite different between normal human fibroblasts and endothelial cells, International Journal of Oncology, 87-95, 20050701
  30. Prediction of individual response to platinum/paclitaxel combination using novel marker genes in ovarian cancers, Mol Cancer Ther, 5(3), 767-775, 20060301
  31. Chemosensitivity prediction in esophageal squamous cell carcinoma: Novel marker genes and efficacy-prediction formulae using their expression data, Int J Oncol, 28, 1153-1162, 20060501
  32. Human carboxylesterase 1A2 expressed from carboxylesterase 1A1 and 1A2 genes is a potent predictor of CPT-11 cytotoxicity in vitro, PHARMACOGENETICS AND GENOMICS, 17(1), 1-10, 2007
  33. Differential regulation of DEC2 among hypoxia-inducible genes in endometrial carcinomas, ONCOLOGY REPORTS, 17(4), 871-878, 2007
  34. EGFR activating aberration occurs independently of other genetic aberrations or telomerase activation in adenocarcinoma of the lung, ONCOLOGY REPORTS, 17(6), 1405-1411, 2007
  35. Hypoxia inducible factor-1 influences sensitivity to paclitaxel of human lung cancer cell lines under normoxic conditions, CANCER SCIENCE, 98(9), 1394-1401, 2007
  36. Human carboxylesterase 1A2 expressed from carboxylesterase 1A1 and 1A2 genes is a potent predictor of CPT-11 cytotoxicity in vitro, PHARMACOGENETICS AND GENOMICS, 17(1), 1-10, 2007
  37. EGFR activating aberration occurs independently of other genetic aberrations or telomerase activation in adenocarcinoma of the lung, Oncology Reports, 17, 1405-1411, 20070601
  38. Exploration of the genes responsible for unlimited proliferation of immortalized lung fibroblasts, EXPERIMENTAL LUNG RESEARCH, 34(7), 373-390, 2008
  39. Exploration of the genes responsible for unlimited proliferation of immortalized lung fibroblasts., Exp Lung Res, 34(7), 373-390, 20080901
  40. EMP3 as a tumor suppressor gene for esophageal squamous cell carcinoma., Cancer Letters, 274(2009), 25-32, 20090201
  41. EMP3 as a candidate tumor suppressor gene for solid tumors., Expert Opin. Ther. Targets., 13(7), 811-822, 20090701
  42. Activation of the hypoxia-inducible factor-1 in overloaded temporomandibular joint, and induction of osteoclastogenesis, BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 393(4), 800-805, 2010
  43. Carcinogenesis and cellular immortalization without persistent inactivation of p16/Rb pathway in lung cancer, International Journal of Oncology, 36(5), 1217-1227, 20100501
  44. Basic helix-loop-helix transcription factor DEC1 negatively regulates CyclinD1, Journal of Pathology, 224(3), 420-429, 20110701
  45. Interactive effects of cell therapy and rehabilitation realize the full potential of neurogenesis in brain injury model, Neurosci Lett, 555(25), 73-78, 20131001
  46. Differential regulation of DEC2 among hypoxia-inducible genes in endometrial carcinomas, ONCOLOGY REPORTS, 17(4), 871-878, APR 2007
  47. The A Allele at rs13419896 of EPAS1 Is Associated with Enhanced Expression and Poor Prognosis for Non-Small Cell Lung Cancer, PLOS ONE, 10(8), AUG 11 2015
  48. Selection of a novel drug-response predictor in esophageal cancer: A novel screening method using microarray and identification of IFITM1 as a potent marker gene of CDDP response, INTERNATIONAL JOURNAL OF ONCOLOGY, 32(2), 413-423, FEB 2008
  49. A Chemical Modulator of p53 Transactivation that Acts as a Radioprotective Agonist, MOLECULAR CANCER THERAPEUTICS, 17(2), 432-442, FEB 2018
  50. Differentiated embryo chondrocyte plays a crucial role in DNA damage response via transcriptional regulation under hypoxic conditions, PLOS ONE, 13(2), FEB 21 2018
  51. Human carboxylesterase 1A2 expressed from carboxylesterase 1A1 and 1A2 genes is a potent predictor of CPT-11 cytotoxicity in vitro, PHARMACOGENETICS AND GENOMICS, 17(1), 1-10, JAN 2007
  52. UCHL1 provides diagnostic and antimetastatic strategies due to its deubiquitinating effect on HIF-1 alpha, Nature Communications, 6, JAN 2015
  53. Mitochondria are required for ATM activation by extranuclear oxidative stress in cultured human hepatoblastoma cell line Hep G2 cells, BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 443(4), 1286-1290, JAN 24 2014
  54. Human mismatch repair gene, MLH1, is transcriptionally repressed by the hypoxia-inducible transcription factors, DEC1 and DEC2, ONCOGENE, 27(30), 4200-4209, JUL 2008
  55. The transcribed-ultraconserved regions in prostate and gastric cancer: DNA hypermethylation and microRNA-associated regulation, ONCOGENE, 35(27), 3598-3606, JUL 7 2016
  56. Prediction of individual response to platinum/paclitaxel combination using novel marker genes in ovarian cancers, MOLECULAR CANCER THERAPEUTICS, 5(3), 767-775, MAR 2006
  57. Targeted gene delivery to human osteosarcoma cells with magnetic cationic liposomes under a magnetic field, INTERNATIONAL JOURNAL OF ONCOLOGY, 22(5), 1065-1071, MAY 2003
  58. Chemosensitivity prediction in esophageal squamous cell carcinoma: Novel marker genes and efficacy-prediction formulae using their expression data, INTERNATIONAL JOURNAL OF ONCOLOGY, 28(5), 1153-1162, MAY 2006
  59. OASIS modulates hypoxia pathway activity to regulate bone angiogenesis, SCIENTIFIC REPORTS, 5, NOV 12 2015
  60. Unique action determinants of double acting topoisomerase inhibitor, TAS-103, INTERNATIONAL JOURNAL OF ONCOLOGY, 19(5), 921-927, NOV 2001
  61. Hypoxia-inducible factor-1 alpha polymorphisms associated with enhanced transactivation capacity, implying clinical significance, CARCINOGENESIS, 24(11), 1779-1783, NOV 2003
  62. Single nucleotide polymorphism in the hypoxia-inducible factor-1 alpha gene in colorectal carcinoma, ONCOLOGY REPORTS, 12(5), 1033-1037, NOV 2004
  63. Association of EPAS1 Gene rs4953354 Polymorphism with Susceptibility to Lung Adenocarcinoma in Female Japanese Non-Smokers, JOURNAL OF THORACIC ONCOLOGY, 9(11), 1709-1713, NOV 2014
  64. Aberrant methylation of DPYD promoter, DPYD expression, and cellular sensitivity to 5-fluorouracil in cancer cells, CLINICAL CANCER RESEARCH, 10(20), 7100-7107, OCT 15 2004
  65. High-flow arteriovenous malformation of the mandible: treatment and 7-year follow-up, BRITISH JOURNAL OF ORAL & MAXILLOFACIAL SURGERY, 41(5), 348-350, OCT 2003
  66. IL-1 beta-mediated up-regulation of DEC1 in human gingiva cells via the Akt pathway, JOURNAL OF CELLULAR BIOCHEMISTRY, 113(10), 3246-3253, OCT 2012
  67. Concise prediction models of anticancer efficacy of 8 drugs using expression data from 12 selected genes, INTERNATIONAL JOURNAL OF CANCER, 111(4), 617-626, SEP 10 2004
  68. Hypoxia inducible factor-1 influences sensitivity to paclitaxel of human lung cancer cell lines under normoxic conditions, CANCER SCIENCE, 98(9), 1394-1401, SEP 2007